Little is known about the extent of cortical and subcortical volumetric alterations that may occur within the first year of HIV infection [primary HIV infection (PHI)].
Introduction
HIV enters the central nervous system (CNS) soon after initial infection in the form of free virions or by way of immune cells traveling across the blood-brain barrier (BBB) and stimulates immune activation [1] . Markers of systemic and microglial immune activation, such as CD8 þ T-cell count and neopterin, are elevated in cerebrospinal fluid (CSF) during untreated primary HIV infection (PHI; defined as <1 year after exposure) and remain elevated with chronic HIV infection (CHI) (>1 year) in the absence of combination antiretroviral therapy (cART) [2, 3] . Viral and immunopathogenic changes that occur during PHI may facilitate the subsequent neurodegeneration and cortical and subcortical volume loss reported in CHI [4, 5] .
However, the existence and extent of brain tissue volume changes, early in the course of HIV infection, are incompletely characterized. One prior study revealed reduced total cortical volume and enlarged third ventricle in PHI, though the study included HIV-infected individuals receiving cART [6, 7] . Thus, the natural course of untreated HIV-dependent volume changes is not established, as early initiation of cART may preclude further neural injury. Early regional volume loss may be responsible for downstream cognitive performance deficits commonly associated with chronic disease [8] . For example, a reduction in putamen size is associated with impaired motor performance in CHI [9] . In this study, we obtained cortical and subcortical volumetrics in cART-naïve PHI individuals and investigated relationships among regional brain volumes, duration of infection, laboratory measures, and neuropsychological performance.
Materials and methods

Participants
The study included PHI (n ¼ 47) and HIV-uninfected (n ¼ 18) participants that have been previously described [2, 10, 11] . cART-naïve PHI individuals were assessed within 1 year of acquiring HIV, as confirmed by recent negative result on HIVantibody testing or results of a lesssensitive enzyme immunoassay test [2] . The date of HIV exposure was estimated as 14 days before onset of seroconversion symptoms (n ¼ 38/47) or as the date halfway between the last negative and first positive HIV test (n ¼ 9/47). The institutional review board at the University of California, San Francisco approved the protocol, and informed consent was obtained from all participants.
Specimen sampling, processing, and laboratory studies Clinical examination (including medical and neurological) and laboratory studies (CSF and blood) were obtained. Detailed laboratory analysis for CD4 þ , CD8 þ T-cell counts, CSF neopterin, neurofilament light chain (NFL), CSF : plasma albumin ratio, and blood and CSF HIV RNA levels have been previously described [10, 11] .
Neuropsychometric performance evaluation
A brief neuropsychometric performance battery was administered to participants and included four assessments: timed gait, grooved pegboard, finger tapping, and digit symbol, as previously described [10] . To control for social and demographic variability in the groups, z-scores for neuropsychological testing were calculated on the basis of comparing raw scores to age, sex, ethnicity, and level of education matched norms. A neuropsychological performance z-score (NPZ-4) was calculated by averaging the four z-scores from the battery [12] .
Neuroimaging acquisition and analyses T1-weighted three-dimensional magnetization-prepared rapid acquisition gradient echo (TR/T1/TE ¼ 2300/ 950/3 ms, voxel size ¼ 1.0 Â 1.0 Â 1.0 mm 3 , flip angle 78, bandwidth ¼ 200 Hz/pixel) scans were acquired using a 4T Siemens/Bruker MedSpec scanner (Siemens AG, Erlangen, Bavaria, Germany).
Volumetric segmentation was performed using the FreeSurfer 5.1 image analysis suite (Harvard University, Boston, Massachusetts, USA) [13] . Regional volumes were normalized to total intracranial volume (ICV) using a least squares residual regression model. ICV was similar across the two groups (P ¼ 0.383). Normalized volumes were calculated for the amygdala, caudate, putamen, thalamus, third ventricle, corpus callosum, and total white and gray matter, regions previously implicated in HIV infection [4, 7] .
Statistical analysis
Demographic characteristics are summarized using means and SDs for the continuous variables with approximately normal distributions (age, education, and NPZ-4), and median and first and third quartiles (Q 1 , Q 3 ) for skewed continuous variables [CD4 þ , CD8 þ T-cell counts, plasma and CSF neopterin, CSF : plasma albumin ratio, and CSF white blood count (WBC)], and compared between groups using Student's t test and Wilcoxon rank-sum test, respectively. For groupwise regional volume comparisons, one-way analysis of covariance was used with age as a covariate. Regions that showed adjusted volumetric differences between the PHI and HIV-group at the 0.10 level were further studied in the PHI group using two-tailed partial correlation analyses (partialling out age) to examine the associations of regional volumes to measures of HIV infection, neuropsychological performance, or duration of infection. Appropriate normality transformations (square root and logarithm) were used for the skewed variables. No corrections for multiple comparisons were included in the analysis because of the exploratory nature of the study. All statistical analyses used SPSS 22 (IBM Corp., Armonk, New York, USA).
Results
Participants PHI participants were assessed at a median 106 days post estimated infection. Table 1 compares the demographic and laboratory data between the two groups. The PHI and control groups did not differ significantly in sex, age, education, or ethnicity. As expected, PHI had lower CD4 þ T-cell count and higher CD8 þ T-cell count and CSF WBC counts. CSF : plasma albumin ratio, a measure of BBB integrity, was similar in the two groups, whereas CSF neopterin, a marker of neuroinflammation, was elevated in the PHI group.
Putamen volume is reduced in primary HIV infection
The relative groupwise comparisons of each of the eight target regions can be seen in Fig. 1a . Total gray and white matter volumes were similar for the two groups, whereas a trend-level moderate reduction of putamen volume (P ¼ 0.076, adjusted Cohen's d ¼ 0.5 after controlling for age) was seen for PHI compared with HIV-uninfected individuals (Fig. 1b ). Cohen's d is a measure of effect size and is in units of SD. This finding of d ¼ 0.5 describes a medium-level effect, that, taken together with the trend-level P value, points to a probable, appreciable reduction in putamen volume. It should be noted that although the third ventricle appears to have a larger relative groupwise volume difference, this difference is NS (P ¼ 0.36) and potentially reflects the high coefficient of variation in this region compared with the putamen (average CV 3rdVentricle ¼ 28% versus average CV Putamen ¼ 9%). Because of this marginal evidence of a putamen volume reduction in early HIV infection, we next explored associations between volume and laboratory measures.
Putamen volume correlates with systemic immune health measures
In PHI participants, both CD4 þ T-cell count and CD4 þ /CD8 þ T-cell count ratio, measures of HIV-related immune status, showed significant positive correlations with putamen volume (CD4 þ T-cell count: r p ¼ 0.323, P ¼ 0.030; CD4 þ /CD8 þ ratio: r p ¼ 0.304, P ¼ 0.045) [ Fig. 1c (i) ]. PHI putamen volume did not significantly correlate with plasma HIV RNA or other CSF measures.
Putamen volume correlates with neuropsychometric performance
The putamen is a basal ganglia structure and is an important component of motor control pathways. Therefore, we anticipated a relationship between PHI putamen volume and psychomotor performance. We observed significant correlations between putamen volume and normed z-scores from timed gait (r p ¼ 0.398; P ¼ 0.009), finger tapping (r p ¼ 0.312; P ¼ 0.039), digit symbol substitution (r p ¼ 0.331; P ¼ 0.028), and the global NPZ-4 (r p ¼ 0.442; P ¼ 0.003) [ Fig. 1c (ii) ]. Associations between putamen volume and performance from timed gait and NPZ4 were only significant in the PHI cohort.
Putamen volume decreases with longer duration of infection
Putamen volume had a negative relationship with increasing estimated duration of infection (P ¼ 0.009) (Fig. 1d ). Although this study is cross-sectional, this finding may imply a continuous relationship between duration of infection and putamenal volume loss even during the first year of infection.
Discussion
In this study, we examined regional volumetric differences between individuals within the first year of HIV infection and HIV-uninfected individuals. We observed a reduction in putamen volume in PHI that associated with duration of infection, neuropsychometric performance, and immune system measures.
The putamen (and the basal ganglia collectively) has been shown to be selectively injured in a number of diseases, with volume regional loss reported in type 1 diabetes [14] , multiple sclerosis [15] , and Alzheimer's disease [16] . The mechanistic relationships between these conditions and HIV may be potentially related to inflammation or vascular injury and warrant further investigation. Though previous studies have reported basal ganglia volume loss in HIV, including in chronically infected participants with cognitive impairment [17] , the mechanism underlying the selective injury to this area remains unclear. In HIVassociated dementia, HIV replication preferentially occurs in perivascular macrophages in the basal ganglia [18] , which in its early stages associates with basal ganglia hypermetabolism on brain PET [19] . Interestingly, the basal ganglia is the earliest region to manifest inflammation in magnetic resonance studies of acute HIV infection [20] , possibly a result of selective impairment of endothelial tight junctions observed in this brain region in HIV [21] . Thus, it is possible that even early during infection, due to a locally compromised BBB in the basal ganglia, the putamen is an early target of viral infection and inflammatory injury, leading to early tissue compromise and volume loss.
These findings, along with previous reports from the same cohort using multiple modalites [2, 10, 11] , imply a comprehensive narrative of the mechanisms that underlie observed pathophsyiological changes seen with early HIV infection. The elevated CSF : plasma albumin ratio observed in a larger sample from this cohort and elevated CSF WBC and neopterin reported here implies compromised BBB integrity and CNS immune activation in PHI [2] . The observed elevated NFL in some HIVþ individuals in this cohort [10] suggests neuronal degradation; however, we observed no association between NFL and putamen volume (r p ¼ À0.103, P ¼ 0.497) or other brain volumes. Previously observed changes in white matter integrity seen during the first year of infection [11] and our current report of putamen volume changes support the concept that early inflammation and neuronal injury measurably impact brain structure. Although the putamenal volumetric difference was moderate (P ¼ 0.076, d ¼ 0.5), its biological meaning may be supported by the correlations we observed with markers of systemic immune status and duration of HIV infection, possibly reflecting cumulative exposure to immune and viral pathogenesis. Furthermore, the biologic significance of putaminal volume changes is supported by the relationships noted between psychomotor performance and putamen volume. These suggest that subtle changes in brain volume could underlie neuropsychological deficits described during early infection [7] . Finally, with increasing duration of infection, both functional and structural connections (e.g. prominent white matter tracts) are affected, possibly leading to the more widespread neurocognitive changes seen with CHI [11, 22] .
The study has several limitations. Because this cohort was designed specifically to examine early HIV-associated changes, the HIV-uninfected group was small compared with the PHI group. Additionally, no adjustments for multiple comparisons were made, exposing the results to potential false positive results. Further confirmation of our findings is needed from independent studies. Finally, we did not classify the participants according to HIV-associated cognitive disorder criteria for this analysis as we included a limited testing battery and did not formally assess functional status in this cohort [23] .
Conclusion
The results reported here add to the continually growing body of evidence describing CNS changes seen early after HIV infection. Collectively, they suggest that early intervention may mitigate brain damage, but additional clinical trials are needed.
